RPRX

Stats

Summary

royalty pharma is the industry leader in acquiring revenue-producing intellectual property – principally royalty interests in marketed and late stage biopharmaceutical products with $13 billion in assets. since inception in 1996, royalty pharma and its predecessors have invested approximately $5.8 billion to assemble a leading portfolio of royalty interests in pharmaceutical and biopharmaceutical products. royalty pharma’s strategy has been to acquire royalty interests in leading pharmaceutical and biotechnology products and hold these interests as part of a portfolio, seeking to diversify its revenue base across product and therapeutic classes. royalty pharma captures many of the strong and predictable aspects of the pharmaceutical industy while limiting the typical risks of biopharmaceutical companies. royalty pharma currently owns a diversified portfolio of royalty interests in several high- quality blockbuster biopharmaceutical products, including abbott’s humira®, j&j/merck’s remi

Market Cap: 13.3 Billion

Primary Exchange: NASDAQ

Website: https://www.royaltypharma.com

Shares Outstanding: 447 Million

Float: 0

Dividend: 0.7943031879201214 (0.03%)

Beta: 0.6336299750752905

Sector: Manufacturing

Industry: Pharmaceutical Preparation Manufacturing

Ethical Flags

Longest drawdown: 1102 trading days

From: 2013-09-23 To: 2018-01-31

Lowest Point:

Ex-Date	Payment Date	Record Date	Declared Date	Amount	Flag	Dividend Type	Qualified	Indicated
2020-09-14	2020-09-30	2020-09-15	2020-09-02	0.15	Cash
2020-11-19	2020-12-15	2020-11-20	2020-10-15	0.15	Cash
2023-02-15	2023-03-15	2023-02-16	2023-01-09	0.2	Cash
2023-05-18	2023-06-15	2023-05-19	2023-04-17	0.2	Cash
2023-08-17	2023-09-15	2023-08-18	2023-07-17	0.2	Cash
2023-11-16	2023-12-15	2023-11-17	2023-10-16	0.2	Cash
2024-02-15	2024-03-15	2024-02-16	2024-01-19	0.21	Cash

Ex-Date	Declared Date	Record Date	Payment Date	Ratio	To Factor	For Factor